New Jardiance (Empagliflozin) A diabetes drug orally showed a reduced risk of cardiovascular events in patients with type diabetes 2. the drug is a highly selective inhibitor oral glucose co-transporter sodium (SGLT-2), which acts by blocking glucose reabsorption in the kidney that reduces blood glucose levels. It is approved for use for the treatment of type 2 diabetes in adults.
Diabetic Drug Jardiance (Empagliflozin) showed risk reduction for cardiovascular deaths
Boehringer Ingelheim and Eli Lilly, two of the leading pharmaceutical companies in the world continually strive to focus on the needs of the patient in the treatment of diabetes. Diabetes is a chronic disease that is either due to the body’s inability to synthesize normal insulin or inefficient use synthesized hormone insulin. Diabetes continues to increase the risk of high blood pressure, obesity and cardiovascular disease.
‘New Jardiance (Empagliflozin) a drug for diabetes orally reduced the risk of cardiovascular death in patients with diabetes type 2. The results of the clinical trial EMPA-REG were presented at the American Diabetes Association (ADA) Scientific Sessions 76th in New Orleans. “
The trial result EMPA-REG established cardiovascular disease in people with diabetes. It was conducted in more than 7,000 patients from 42 countries worldwide. The study was also conducted to evaluate the effect of Jardiance in reducing the risk of cardiovascular disease. It was found that the risk of cardiovascular death was reduced by 38% and drug safety profile was consistent compared with previous trials.
The results of the clinical trial empathic REG Eli Lilly and Boehringer were presented at the sessions of the American Diabetes Association (ADA) 76th Scientific in New Orleans. Reduced risk of cardiovascular disease was observed in diabetic patients with Jardiance (empagliflozin) compared to placebo.
The data analyzed the efficacy of the drug according to the patient’s age. Study participants were grouped into three categories of people under 65 years, 65-74 years and people over 75 years. The three categories showed a reduced risk of heart failure and cardiovascular deaths. It was also found that it was consistent with the subgroups of low-density lipoprotein for the combination of cardiovascular death, nonfatal myocardial infarction or stroke.
Professor Hans-Juergen Woerle, Global Vice President Medicine at Boehringer Ingelheim stated that the results analyzed test results EMPA-REG reduce the risk of cardiovascular death and heart failure in patients with type 2 diabetes also said that through research continuous diabetic Alliance between Boehringer Ingelheim and Eli Lilly and Company will continue to manage the risk of cardiovascular disease in the diabetic population.
This article was originally published on medindia.net
Posted in: health news